Syncona (LSE:SYNC), the life science investor, said portfolio company OMass Therapeutics has raised $310 million in an oversubscribed Series C round. Syncona committed $10.1 million to the financing and has written up its OMass holding by £4.7 million, a 9.4% uplift on its 30 June 2026 value.
What Syncona announced about OMass
In an announcement released at 07:00 on 15 October 2026, Syncona said OMass Therapeutics had closed a $310 million (about £230 million) Series C financing. Syncona committed $10.1 million (about £7.5 million) alongside a global syndicate of investors.
The round was co-led by Bain Capital Life Sciences, Forbion and Novo Holdings, with Janus Henderson Investors, SV Health Investors and Jefferson Life Sciences also participating. Syncona said all existing investors took part, including Oxford Science Enterprises, GV, Northpond Ventures, Sanofi Ventures, British Patient Capital and the University of Oxford.
Valuation impact for Syncona
Syncona said its OMass holding has been "written up by £4.7 million (1p per share)", a 9.4% uplift to the 30 June 2026 valuation. Including £1.7 million of new capital invested since 30 June 2026, the holding is valued at £56.0 million. Syncona's stake will be 16.1% once the full Series C is drawn down. The company noted that currency conversions use the September monthly average rate.
The announcement does not give an updated figure for Syncona's overall net asset value or capital pool.
Why the financing matters
OMass is a University of Oxford spin-out developing small molecule medicines for rare and immunological diseases using its OdyssION platform. Syncona (LSE:SYNC) led its Series A in 2018, and OMass has now raised about $475 million (£360 million) in total.
Edward Hodgkin, Managing Partner of Syncona Investment Management and an OMass board director, said: "The strength and calibre of this group is an important external validation of OMass' technology and progress to date and provide the company with the ability to execute on its ambitions." He added: "It is encouraging to see high-quality UK early-stage companies attract capital at scale in areas of high innovation."
Ros Deegan, Chief Executive of OMass, said: "This financing comes at an exciting point in OMass' evolution as we advance OMS1620 into the clinic with our SLC15A4 inhibitor poised to follow."
The proceeds will fund the progression of lead programme OMS1620, a small molecule for congenital adrenal hyperplasia, into the clinic and "through Phase 2 development". The financing will also support work in ACTH-dependent Cushing's syndrome, early pipeline activity and the "generation of initial clinical data for its next candidate".
Risks investors may weigh
OMass's lead programme is entering the clinic, and drug development carries the risk of setbacks or failure at any stage. The announcement gives no dates for clinical milestones. The write-up reflects the price of a private funding round rather than a market price, so the value of the holding could change as OMass progresses. The company put the £4.7 million uplift at 1p per share.
What LSE stocks watchers may track next
Market participants following UK shares in life sciences may look for news on when OMS1620 enters clinical trials, progress with the SLC15A4 inhibitor, and how the new valuation feeds into Syncona's next net asset value update. Ms Deegan said OMass is "entering our next phase with the resources to translate that progress into a portfolio of clinically differentiated medicines for patients."
Syncona's portfolio after the OMass round
The Series C gives OMass a large funding base and a recognised group of new investors, while adding £4.7 million to the value of Syncona's holding. For followers of the UK stock market, the announcement offers an external price check on one of Syncona's portfolio companies, with clinical progress likely to be the main driver of the holding's value from here.
_11_16_2026_14_47_34_233787.jpg)





Please wait processing your request...